310 related articles for article (PubMed ID: 24766216)
1. Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma.
Yoshimura M; Ishizawa J; Ruvolo V; Dilip A; Quintás-Cardama A; McDonnell TJ; Neelapu SS; Kwak LW; Shacham S; Kauffman M; Tabe Y; Yokoo M; Kimura S; Andreeff M; Kojima K
Cancer Sci; 2014 Jul; 105(7):795-801. PubMed ID: 24766216
[TBL] [Abstract][Full Text] [Related]
2. Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185.
Tabe Y; Kojima K; Yamamoto S; Sekihara K; Matsushita H; Davis RE; Wang Z; Ma W; Ishizawa J; Kazuno S; Kauffman M; Shacham S; Fujimura T; Ueno T; Miida T; Andreeff M
PLoS One; 2015; 10(9):e0137210. PubMed ID: 26340096
[TBL] [Abstract][Full Text] [Related]
3. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma.
Zhang K; Wang M; Tamayo AT; Shacham S; Kauffman M; Lee J; Zhang L; Ou Z; Li C; Sun L; Ford RJ; Pham LV
Exp Hematol; 2013 Jan; 41(1):67-78.e4. PubMed ID: 22986101
[TBL] [Abstract][Full Text] [Related]
4. XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways.
Chakravarti N; Boles A; Burzinski R; Sindaco P; Isabelle C; McConnell K; Mishra A; Porcu P
Sci Rep; 2024 Apr; 14(1):9305. PubMed ID: 38653804
[TBL] [Abstract][Full Text] [Related]
5. Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1.
Sekihara K; Saitoh K; Han L; Ciurea S; Yamamoto S; Kikkawa M; Kazuno S; Taka H; Kaga N; Arai H; Miida T; Andreeff M; Konopleva M; Tabe Y
Oncotarget; 2017 May; 8(21):34552-34564. PubMed ID: 28388555
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53/mTOR pathway.
Zhao C; Yang ZY; Zhang J; Li O; Liu SL; Cai C; Shu YJ; Pan LJ; Gong W; Dong P
J Transl Med; 2022 Sep; 20(1):434. PubMed ID: 36180918
[TBL] [Abstract][Full Text] [Related]
7. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma.
Zheng Y; Gery S; Sun H; Shacham S; Kauffman M; Koeffler HP
Cancer Chemother Pharmacol; 2014 Sep; 74(3):487-95. PubMed ID: 25030088
[TBL] [Abstract][Full Text] [Related]
8. Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma.
Jardin F; Pujals A; Pelletier L; Bohers E; Camus V; Mareschal S; Dubois S; Sola B; Ochmann M; Lemonnier F; Viailly PJ; Bertrand P; Maingonnat C; Traverse-Glehen A; Gaulard P; Damotte D; Delarue R; Haioun C; Argueta C; Landesman Y; Salles G; Jais JP; Figeac M; Copie-Bergman C; Molina TJ; Picquenot JM; Cornic M; Fest T; Milpied N; Lemasle E; Stamatoullas A; Moeller P; Dyer MJ; Sundstrom C; Bastard C; Tilly H; Leroy K
Am J Hematol; 2016 Sep; 91(9):923-30. PubMed ID: 27312795
[TBL] [Abstract][Full Text] [Related]
9. XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis.
Zhu ZC; Liu JW; Yang C; Zhao M; Xiong ZQ
Cell Death Dis; 2019 May; 10(6):395. PubMed ID: 31113936
[TBL] [Abstract][Full Text] [Related]
10. Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma.
Boons E; Vanstreels E; Jacquemyn M; Nogueira TC; Neggers JE; Vercruysse T; van den Oord J; Tamir S; Shacham S; Landesman Y; Snoeck R; Pannecouque C; Andrei G; Daelemans D
EBioMedicine; 2015 Sep; 2(9):1102-13. PubMed ID: 26501108
[TBL] [Abstract][Full Text] [Related]
11. Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.
Breit MN; Kisseberth WC; Bear MD; Landesman Y; Kashyap T; McCauley D; Kauffman MG; Shacham S; London CA
BMC Vet Res; 2014 Jul; 10():160. PubMed ID: 25022346
[TBL] [Abstract][Full Text] [Related]
12. Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.
Yang J; Bill MA; Young GS; La Perle K; Landesman Y; Shacham S; Kauffman M; Senapedis W; Kashyap T; Saint-Martin JR; Kendra K; Lesinski GB
PLoS One; 2014; 9(7):e102983. PubMed ID: 25057921
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition.
Azmi AS; Muqbil I; Wu J; Aboukameel A; Senapedis W; Baloglu E; Bollig-Fischer A; Dyson G; Kauffman M; Landesman Y; Shacham S; Philip PA; Mohammad RM
Sci Rep; 2015 Nov; 5():16077. PubMed ID: 26536918
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1.
Luedtke DA; Su Y; Liu S; Edwards H; Wang Y; Lin H; Taub JW; Ge Y
J Cell Mol Med; 2018 Dec; 22(12):6099-6111. PubMed ID: 30596398
[TBL] [Abstract][Full Text] [Related]
16. The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia.
Vercruysse T; De Bie J; Neggers JE; Jacquemyn M; Vanstreels E; Schmid-Burgk JL; Hornung V; Baloglu E; Landesman Y; Senapedis W; Shacham S; Dagklis A; Cools J; Daelemans D
Clin Cancer Res; 2017 May; 23(10):2528-2541. PubMed ID: 27780859
[No Abstract] [Full Text] [Related]
17. Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
Muqbil I; Aboukameel A; Elloul S; Carlson R; Senapedis W; Baloglu E; Kauffman M; Shacham S; Bhutani D; Zonder J; Azmi AS; Mohammad RM
Cancer Lett; 2016 Dec; 383(2):309-317. PubMed ID: 27693556
[TBL] [Abstract][Full Text] [Related]
18. CRISPR-Cas9 Screening of Kaposi's Sarcoma-Associated Herpesvirus-Transformed Cells Identifies XPO1 as a Vulnerable Target of Cancer Cells.
Gruffaz M; Yuan H; Meng W; Liu H; Bae S; Kim JS; Lu C; Huang Y; Gao SJ
mBio; 2019 May; 10(3):. PubMed ID: 31088931
[TBL] [Abstract][Full Text] [Related]
19. Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.
Crochiere M; Kashyap T; Kalid O; Shechter S; Klebanov B; Senapedis W; Saint-Martin JR; Landesman Y
BMC Cancer; 2015 Nov; 15():910. PubMed ID: 26573568
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors.
Conforti F; Zhang X; Rao G; De Pas T; Yonemori Y; Rodriguez JA; McCutcheon JN; Rahhal R; Alberobello AT; Wang Y; Zhang YW; Guha U; Giaccone G
Cancer Res; 2017 Oct; 77(20):5614-5627. PubMed ID: 28819023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
